Blue Trust Inc. Increases Stock Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT)

Blue Trust Inc. boosted its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) by 47.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 17,225 shares of the biotechnology company’s stock after buying an additional 5,567 shares during the quarter. Blue Trust Inc.’s holdings in Corcept Therapeutics were worth $797,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Capital Performance Advisors LLP bought a new position in Corcept Therapeutics in the 3rd quarter worth about $25,000. Kathleen S. Wright Associates Inc. purchased a new position in shares of Corcept Therapeutics during the third quarter worth about $36,000. USA Financial Formulas bought a new position in shares of Corcept Therapeutics in the fourth quarter worth approximately $54,000. GAMMA Investing LLC raised its stake in Corcept Therapeutics by 85.4% in the third quarter. GAMMA Investing LLC now owns 2,490 shares of the biotechnology company’s stock valued at $115,000 after purchasing an additional 1,147 shares in the last quarter. Finally, KBC Group NV lifted its position in Corcept Therapeutics by 21.3% during the third quarter. KBC Group NV now owns 2,822 shares of the biotechnology company’s stock valued at $131,000 after purchasing an additional 496 shares during the last quarter. 93.61% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Corcept Therapeutics

In other Corcept Therapeutics news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $59.88, for a total transaction of $131,736.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider William Guyer sold 3,394 shares of the company’s stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $48.97, for a total transaction of $166,204.18. Following the completion of the transaction, the insider now owns 5,796 shares of the company’s stock, valued at approximately $283,830.12. The trade was a 36.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 38,011 shares of company stock valued at $1,951,268. Insiders own 20.50% of the company’s stock.

Corcept Therapeutics Price Performance

CORT opened at $61.53 on Thursday. The company’s 50-day simple moving average is $55.55 and its two-hundred day simple moving average is $46.50. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.64 and a current ratio of 3.70. The stock has a market capitalization of $6.45 billion, a P/E ratio of 48.83 and a beta of 0.56. Corcept Therapeutics Incorporated has a 52-week low of $20.84 and a 52-week high of $62.98.

Corcept Therapeutics (NASDAQ:CORT) last issued its earnings results on Wednesday, October 30th. The biotechnology company reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.14. The company had revenue of $182.55 million for the quarter, compared to analysts’ expectations of $171.97 million. Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. The firm’s quarterly revenue was up 47.7% on a year-over-year basis. During the same quarter last year, the company posted $0.28 earnings per share. As a group, analysts predict that Corcept Therapeutics Incorporated will post 1.35 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on CORT shares. Sandler O’Neill reissued a “buy” rating on shares of Corcept Therapeutics in a research note on Friday, October 18th. HC Wainwright reissued a “buy” rating and set a $80.00 price objective on shares of Corcept Therapeutics in a research report on Thursday, October 31st. Finally, StockNews.com cut shares of Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 25th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Corcept Therapeutics has a consensus rating of “Buy” and a consensus price target of $65.25.

Corcept Therapeutics Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.